Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul 03080, Korea.
Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul 06351, Korea.
Eur Heart J Cardiovasc Imaging. 2022 Jul 21;23(8):1108-1116. doi: 10.1093/ehjci/jeab187.
We investigated the prognostic role of left ventricular global longitudinal strain (LV-GLS) and its incremental value to established risk models for predicting sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM).
LV-GLS was measured with vendor-independent software at a core laboratory in a cohort of 835 patients with HCM (aged 56.3 ± 12.2 years) followed-up for a median of 6.4 years. The primary endpoint was SCD events, including appropriate defibrillator therapy, within 5 years after the initial evaluation. The secondary endpoint was a composite of SCD events, heart failure admission, heart transplantation, and all-cause mortality. Twenty (2.4%) and 85 (10.2%) patients experienced the primary and secondary endpoints, respectively. Lower absolute LV-GLS quartiles, especially those worse than the median (-15.0%), were associated with progressively higher SCD event rates (P = 0.004). LV-GLS was associated with an increased risk for the primary endpoint, independent of the LV ejection fraction, apical aneurysm, and 2014 European Society of Cardiology (ESC) risk score [adjusted hazard ratio (aHR) 1.14, 95% confidence interval (CI) 1.02-1.28] or 2011 American College of Cardiology/American Heart Association (ACC/AHA) risk factors (aHR 1.18, 95% CI 1.05-1.32). LV-GLS was also associated with a higher risk for the composite secondary endpoint (aHR 1.06, 95% CI 1.01-1.12). The addition of LV-GLS enhanced the performance of the ESC risk score (C-statistic 0.756 vs. 0.842, P = 0.007) and the 2011 ACC/AHA risk factor strategy (C-statistic 0.743 vs. 0.814, P = 0.007) for predicting SCD.
LV-GLS is an important prognosticator in patients with HCM and provides additional information to established risk stratification strategies for predicting SCD.
我们旨在研究左心室整体纵向应变(LV-GLS)的预后价值及其对肥厚型心肌病(HCM)患者预测心源性猝死(SCD)的既定风险模型的增量价值。
在一个由 835 例 HCM 患者(年龄 56.3 ± 12.2 岁)组成的队列中,使用与供应商无关的软件在核心实验室测量 LV-GLS,中位随访时间为 6.4 年。主要终点为初始评估后 5 年内 SCD 事件,包括适当的除颤器治疗。次要终点为 SCD 事件、心力衰竭入院、心脏移植和全因死亡率的复合终点。20(2.4%)和 85(10.2%)例患者分别经历了主要和次要终点。较低的绝对 LV-GLS 四分位数,尤其是低于中位数(-15.0%)的四分位数,与更高的 SCD 事件发生率相关(P = 0.004)。LV-GLS 与主要终点的风险增加相关,独立于左心室射血分数、心尖瘤和 2014 年欧洲心脏病学会(ESC)风险评分[校正危险比(aHR)1.14,95%置信区间(CI)1.02-1.28]或 2011 年美国心脏病学会/美国心脏协会(ACC/AHA)危险因素(aHR 1.18,95%CI 1.05-1.32)。LV-GLS 也与复合次要终点的较高风险相关(aHR 1.06,95%CI 1.01-1.12)。LV-GLS 的加入增强了 ESC 风险评分(C 统计量为 0.756 比 0.842,P = 0.007)和 2011 年 ACC/AHA 风险因素策略(C 统计量为 0.743 比 0.814,P = 0.007)的预测 SCD 的性能。
LV-GLS 是 HCM 患者的重要预后指标,可为预测 SCD 的既定风险分层策略提供额外信息。